COVID-19 Case Report: An 84-Year-Old Man with Exacerbation of Multiple Comorbidities Due to COVID-19 Managed by a Multidisciplinary Team Using Patient-Reported Outcomes

Abstract

Patient: Male, 84-year-old Final Diagnosis: Acute bronchitis • chronic multiple pain with spondylosis with radiculopathy: lumbar region • chronic renal failure CKD 4 • derailed type 2 diabetes mellitus • diabetes mellitus type 2 • eart failure • hyperuricaemia • progressive aortic stenosis • pulmonary hypertension • SARS-CoV2 Symptoms: Appetite loss • fever • pain • sore throat Medication: — Clinical Procedure: — Specialty: General and Internal Medicine Objective: Unusual clinical course Background: When treating patients with comorbidities who are infected with severe acute respiratory syndrome as a result of SARS-CoV-2, it is crucial to offer multidisciplinary treatment that takes into consideration all of the health conditions with which they have been diagnosed. In particular, clinicians should not lose sight of the patient experience, which we can be assessed with the help of patient-reported outcomes (PROs). Case Report: An 84-year-old man infected with SARS-CoV-2 was already suffering from multiple health conditions, including Type 2 diabetes mellitus. He most likely was receiving cortisone therapy and had chronic pain with spondylosis with radiculopathy, bilateral gonarthrosis following total knee replacement, malaise, and fatigue. The patient received acute inpatient care in a hospital that provides complementary medical therapies. We collected clinical and patient-reported data on quality of life, physical functions, the sensation of pain, psychological well-being, and symptoms while taking into account the degree of chronicity of the conditions, the level of the patient’s pain, and his hospitalization in an isolation ward. We stabilized clinical parameters related to the patient’s main underlying health conditions (blood glucose and pain levels and oxygen saturation). The PROs we collected demonstrated a significant improvement on discharge. Conclusions: Applying PROs can be helpful in obtaining a more comprehensive picture of a patient with COVID-19, in which “the patient is given a voice,” in addition to being assessed by others. The knowledge gained can then be made available to the interdisciplinary treatment team to be incorporated into the treatment plan.

What are the risk factors of hospital length of stay in the novel coronavirus pneumonia (COVID-19) patients? A survival analysis in southwest China

“…Eleanor M. Rees et al carried out systematic analysis and proposed that the bed demand of emergency plan ccould be simulated by LoS, so as to predict the demand of health resources [9]. Knowledge on factors affecting hospital LoS is evolving, and some studies reported that LoS of COVID-19 patients might be affected by the severity of disease, medication, comorbidity and other factors [10][11][12]. However, most reported risk factors related to LoS were clinical predictors and the role of social determinants were still unexplored.…”

Impact of COVID-19 Lockdown Measures on Spanish People with Chronic Pain: An Online Study Survey

“…Besides these few studies, there is little research on how people living through the COVID-19 crisis or those having been infected with the disease perceive and experience the situation [10]. Of particular interest for exploration are the views and experiences of people with chronic pain, as COVID-19 can have a greater impact on them [11], as well as on individuals with physical disabilities in general [3].…”

The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection

“… 7 – 9 Although the clinical presentation for SARS-CoV-2 varies from mild to moderate respiratory illness, older people with pre-existing conditions, such as diabetes, chronic respiratory disease, cardiovascular disease, and cancer are more likely to develop a serious illness with complications and death. 10 This has posed challenges in halting the transmission via droplets due to asymptomatic carriers as well as identifying drugs that might be effective in treating patients who can potentially decompensate later in the clinical course. 11 Consequently, as of off-label use, some existing drugs have been given to patients with COVID-19, including anti-HIV, anti-influenza, and anti-malaria agents.…”